Rivastigmine Patent Expiration

Rivastigmine is Used for managing symptoms of Alzheimer's dementia. It was first introduced by Sandoz Inc in its drug Exelon on Jul 6, 2007. 6 different companies have introduced drugs containing Rivastigmine.


Rivastigmine Patents

Given below is the list of patents protecting Rivastigmine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Exelon US6316023 TTS containing an antioxidant Jan 08, 2019

(Expired)

Sandoz
Exelon US6335031 TTS containing an antioxidant Jan 08, 2019

(Expired)

Sandoz
Exelon US5602176 Phenyl carbamate Feb 11, 2014

(Expired)

Sandoz
Exelon US4948807 Phenyl carbamates Aug 14, 2012

(Expired)

Sandoz



Rivastigmine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Rivastigmine Generic API Manufacturers

Several generic applications have been filed for Rivastigmine. The first generic version for Rivastigmine was by Alvogen Inc and was approved on Aug 31, 2015. And the latest generic version is by Breckenridge Pharmaceutical Inc and was approved on Nov 26, 2019.

Given below is the list of companies who have filed for Rivastigmine generic, along with the locations of their manufacturing plants worldwide.